HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
14. März 2024 11:35 ET
|
HepaRegeniX GmbH
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniXHRX-215 proved to be safe and...
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
30. Juni 2022 13:42 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to...
Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
08. Juni 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
29% of M1a patients achieved metabolic complete response (mCR)mCR patients alive up to >4 years after start of PV-10 treatmentPET tumor response assessment more accurate than 2D EASL or...
Delcath Announces First Quarter 2020 Results
15. Mai 2020 06:30 ET
|
Delcath Systems, Inc.
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 ...
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
05. Mai 2020 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
01. Mai 2020 10:17 ET
|
Delcath Systems, Inc.
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the...
Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019
19. Dezember 2019 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that...
Delcath Systems Announces Postponement of Reverse Stock Split
22. Oktober 2019 07:27 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Systems Announces Ratio for Reverse Stock Split
18. Oktober 2019 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Systems to Participate in Upcoming Investor Conferences
23. September 2019 11:30 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will participate at the following upcoming investor conferences in New...